Better Health for All

EyePoint Pharmaceuticals focuses entirely on developing and commercializing innovative ophthalmic products for serious eye disorders, with 100% of its portfolio (approved products and pipeline candidates like EYP-1901/DURAVYU™ and EYP-2301) addressing conditions such as diabetic macular oedema, non-infectious uveitis, and wet age-related macular degeneration. The company has no revenue from products with well-established negative health outcomes. However, common adverse reactions for DEXYCU were reported by 5-15% of patients, and for YUTIQ, cataract development and increased intraocular pressure were common.

EyePoint entered a three-year contract with Vizient Inc. to offer DEXYCU with enhanced savings, but the pricing relative to production cost is not specified. Vizient's membership includes over 50% of the nation’s acute care providers, 95% of academic medical centers, and over 20% of ambulatory care providers. The company discloses clinical trial information on clinicaltrials.gov, including eligibility, risks, and benefits. EyePoint is developing EYP-1901 and EYP-2301, and made an upfront payment of $1 million to Equinox Science, LLC for vorolanib development. The company commits to adhering to ethical guidelines for clinical trials, registering trials on clinicaltrials.gov, and disclosing results. EyePoint holds patents for its products, including vorolanib, a patent-protected tyrosine kinase inhibitor.

Fair Pay & Worker Respect

The company's employee rating on Glassdoor is 3.5 out of 5 stars, based on 21 reviews.

This rating is in line with the average for the Pharmaceutical & Biotechnology industry. Additionally, 55% of employees would recommend working at the company, and the CEO has a 56% approval rating.

Honest & Fair Business

EyePoint Pharmaceuticals received an FDA warning letter on July 12, 2024, following an inspection from February 6-15, 2024, at its Watertown, Massachusetts facility.

The FDA cited the company for multiple violations, including failure to thoroughly investigate discrepancies, inadequate written procedures for production and process control, and failure to establish and follow adequate control procedures. Specific issues included an atypically high release rate value for a Yutiq batch, three roof leaks causing moisture in manufacturing areas since July 2023, and subpar performance studies that did not scientifically demonstrate blend uniformity. An internal investigation (OOS-23-003) related to a failing release rate analysis, opened on October 13, 2023, remained open through February 8, 2024, past its December 12, 2023 due date. The FDA warned that failure to correct these violations could lead to regulatory or legal action, including seizure and injunction, and may impact approval of new applications or export certificates. No regulatory fines were explicitly mentioned.

No War, No Weapons

The provided articles describe EyePoint Pharmaceuticals' general corporate governance and code of business conduct, emphasizing compliance with applicable laws and regulations, including export control laws.

However, they explicitly state that no quantitative data or specific facts relevant to the 'No War, No Weapons' ethical value, such as revenue from defense contracts, dual-use technology R&D, sales to embargoed regimes, or peacebuilding investments, are presented. Therefore, no KPIs can be scored based on the available evidence.

Planet-Friendly Business

EyePoint Pharmaceuticals was urged by a federal agency to promptly correct at least one environmental compliance violation.

The company implemented an Environmental Policy in 2022 and has a Supplier Code of Conduct. A new 40,000 sq. ft. manufacturing facility in Northbridge, MA, expected to be completed in Q4 2024, is designed with 28 ESG-centric elements, including 3 for water usage, 13 for energy consumption, and 7 for greenhouse gas emissions reduction. This facility will also include an advanced water filtration system, filtration systems, lab fume hoods, and a propane-fired electric generator capable of powering the building for four days.

Safe & Smart Tech

EyePoint Pharmaceuticals received an FDA warning letter in July 2024, following a February 2024 inspection, citing violations of Current Good Manufacturing Practice (CGMP) regulations and deeming a drug product adulterated.

Operators were observed not following written procedures and engaging in un-procedural practices, and a commitment to correct a practice from a 2021 inspection was not fulfilled, indicating inadequate security training effectiveness. Centrifuge tubes for release rate testing were used improperly, and air supply line pressures for manufacturing machines were lower than specified, pointing to issues with unauthorized data use and authentication security. A YUTIQ batch released in October 2022 was associated with two complaints of therapeutic effect failure, suggesting issues with algorithmic harm remediation. The manufacturing process for YUTIQ was validated with a single batch, which did not scientifically demonstrate blend uniformity due to an inadequate sampling plan and resulted in an uninvestigated abnormal low yield of approximately 30%, indicating limited security testing coverage. Roof leaks in manufacturing areas since July 2023, which were not adequately addressed, highlight inconsistent vulnerability management. While the company states it reviews data collection, storage, and processing to collect only necessary information, it also collects data for research and surveys, suggesting some data minimization efforts. The company's privacy policy states personal data is contained behind secured networks, indicating standard encryption. Users have rights to access, rectify, delete, and restrict processing of their personal data, and can opt-out of contact, demonstrating strong user data control. The Audit Committee oversees cybersecurity and privacy risk, receiving quarterly updates and annual reviews of compliance, but the FDA warning letter highlights significant compliance gaps.

Zero Waste & Sustainable Products

EyePoint Pharmaceuticals, Inc. has not incurred any waste disposal violations in the past three years, demonstrating exemplary compliance. The company has a Supplier Code of Conduct, dated October 2022, which requires suppliers to minimize their environmental impact, comply with environmental laws, and reduce emissions and waste.

EyePoint reserves the right to monitor supplier compliance through surveys and certifications. However, the company has no formal waste reduction targets, only vague statements without specific metrics.